Date post: | 08-Jul-2015 |
Category: |
Health & Medicine |
Upload: | alex-asuncion |
View: | 262 times |
Download: | 1 times |
Diana Alcantara-Payawal, MD, MSc, FPCP, FPSG, FPSDE
President , Hepatology Society of the Philippines
Executive Council, Asian Pacific Study of the Liver
Breaking Barriers in Hepatitis Vaccination, Liver
Cancer Prevention
FUNDING RESOURCESWays and Means
EDUCATIONContinuing
medical education
Training program
Public health education
ResearchResearch education
and trainingPJG
Government policyGlobal network
We are the lead national organization committed to the study of the liver in health and in disease involved in research, education, advocacy and formulation of health policies and in partnership with the global community
membership
membership
HSP Strategic Focus
Supporting change through
policy development:
• Advocacy – an independent
voice to
– Call for better responses to viral hepatitis
across the region
– Work in partnership with other
stakeholders, civil society and
governments
• Education - knowledge
– Build advocacy and policy knowledge and
capacity at local levels
– Support local advocates with tools to help
their advocacy
• Policy Development –
evidence
– Conduct research to address knowledge
and data gaps
– Generate knowledge to inform the
development of hepatitis related public
policy
5/02/2014
To reduce the
significant health, social
and economic burden of
Liver diseases in
the Philippines
Major Stakeholder - WHO
• World Health Assembly Resolution WHA63.R18 – May 2010
• WHO Implementation Strategy – made public October 2011
• WHO Framework for Global Action released December 2012
• HSP’s Strategic Plan closely aligned
5/02/2014 4
Private Public Partnership Approach
WHO Strategic
Axis
1. Partnership,
mobilization &
communication
2. Data for policy
and action
3. Prevention of
transmission
4. Screening, care
and treatment
HSP strategic plan:
FOCUS ON POLICY
LEVERS:
1. Advocacy
2. Education &
Capacity Building
3. Policy Development
5
Coordination with national government and private firms
The 4 Axes in the
WHO Framework for
Action
Raising awareness, promoting
partnerships and mobilizing
resources
Evidence-based policy and data for
action
Prevention of transmission
Screening, care and treatment
Axis 1: Raising Awareness, Promoting
Partnerships and Mobilising Resources
Partnership,
mobilization
and
communication
Network of
collaborating
centres
Civil society
collaborations
Resource
mobilization
strategy
External
communication
strategy
Strengthening World
Hepatitis Day activity
Hep B and C
Screening
Fly ABalloon
Lay Fora
– Ensuring that communities understand and support hepatitis related activities
– Developing partnerships between clinical, patient, communities
– Sustainable resourcing/funding for hepatitis related activity.
Vaccination Project in cooperation with
Rotary Club at Juan Luna Elem. School
Axis 2: Evidence-Based Policy and Data for Action
Disease burden
estimates
Impact
assessment
tools
Surveillance and
outbreak
investigation
standards
Country profiles
Research agenda
*
Data for
policy and
action
Axis 2 - Data for Policy and Action
– What data is available?
– What are the gaps in data?
– Is this data accessible to everyone with a stake in hepatitis?
– Is the data written in ways that people can understand and use?
• Tap into available
data banks
• Establish
surveillance systems
• Cost-benefit systems
• 2 014 HSP
consensus guideline
for Hepatitis B and C
Axis 3: Prevention of Transmission
Guidance and tools for immunization for A, B
Safe health care standards and tools
Harm reduction tools for injection drug users
Safe food and water strategies
Safe sexual practice guidance
Prevention
of
transmission
Axis 3 - Prevention of Transmission
– While vaccination programs are implemented, where are there gaps?
– Are there barriers to needle and syringe programs? Does stigma affect access?
– Is there a national infection control policy?
Despite Republic Act 10152 (An Act Providing for Mandatory Basic Immunization Services for Infants and Children:• timely birth dose coverage in the
Philippines was only 40%.• no catch-up program for unimmunized
children beyond the age of 24 months• only 57% and 70% of preterm neonates
and low-birth weight neonates were vaccinated.
Republic Act 7719 National Blood services Act of 1994, was enacted to encourage voluntary blood donation, upgrade blood donation services and facilities, and phase out commercial blood banks to prevent blood contamination.• vigilant surveillance is still necessary
There are up to 18,000 injecting drug users : high risk of needle sharing/ solution
Axis 4: Screening, Care and Treatment
Screening and
counseling resource
package
Diagnostic standards
Care and treatment
guidelines for B andC
Training package for
health care providers
Equity in access to
treatment and drugs
Screening, care and treatment
Axis 4 - Screening, Care and Treatment
– Are there barriers to testing? Payment? Confidentiality?
– Is there accessible health promotion information for people with hepatitis?
– Treatment - Funding? Limits on funding?
– What barriers are there to people accessing treatment?
• limited up-to-date information on the national prevalence of hepatitis B and C, as well as its prevalence in vulnerable groups.
• Screening is currently not covered by thePhilHealth. Stigma towards these infections prevents at-risk individuals from getting screened.
• Hepatitis B and C is undertreated in the Philippines, mostly because of the advanced stage of disease upon diagnosis, and the high cost of treatment.
• Policies against employment and workplace discrimination are inadequately implemented either because many employers are not aware of the Department Of Labor and Employment (DOLE) Department Advisory No. 05 (Series of 2010) or because of the lack of punitive action on violators.
Barrier
LACK OF RESOURCES
LACK OF PUBLIC
AWARENESSS
LACK OF PROVIDER
AWARENESS
Cross-
government
approach with
industry
support
•Carefully crafted
messages based
on what people
wanted/needed to
hear
•Policy report
galvanised political
will
THE GREAT WALL